Figure 1.
Representative example of left ventricular global longitudinal strain from the study sample.
Figure 1.
Representative example of left ventricular global longitudinal strain from the study sample.
Figure 2.
Gender distribution of BAV patients (BAV group—75 patients, male—55 patients, 75.34%, female—18 patients, 24.65%).
Figure 2.
Gender distribution of BAV patients (BAV group—75 patients, male—55 patients, 75.34%, female—18 patients, 24.65%).
Figure 3.
Frequency distribution of phenotypes in BAV group (BAV—bicuspid aortic valve).
Figure 3.
Frequency distribution of phenotypes in BAV group (BAV—bicuspid aortic valve).
Table 1.
Baseline characteristics of the study sample (BSA—body surface area, BMI—body mass index, BP—blood pressure, HR—heart rate, EF—ejection fraction, SF—shorten fraction).
Table 1.
Baseline characteristics of the study sample (BSA—body surface area, BMI—body mass index, BP—blood pressure, HR—heart rate, EF—ejection fraction, SF—shorten fraction).
Parameter | Control Group (n = 54) | BAV Group (n = 73) | p-Value |
---|
Age (years) | 13.00 (10.00–15.00) | 13.00 (9.50–16.00) | 0.928 |
Weight (kg) | 45.50 (36.50–57.75) | 53.00 (32.50–66.00) | 0.285 |
BSA (m2) | 1.41 ± 0.31 | 1.49 ± 0.41 | 0.204 |
Vitamin D (ng/mL) | 26.40 (19.64–35.90) | 30.16 (20.99–54.92) | 0.29 |
pro-BNP (ng/L) | 10.90 (10.00–20.25) | 13.80 (10.00–21.60) | 0.292 |
BMI (kg/m2) | 18.98 ± 3.53 | 19.78 ± 4.41 | 0.274 |
Systolic BP (mmHg) | 110.00 (98.00–120.75) | 111.00 (104.00–121.00) | 0.4 |
Diastolic BP (mmHg) | 66.50 (60.00–72.00) | 65.00 (60.00–70.00) | 0.65 |
HR (b/min) | 83.57 ± 13.51 | 77.23 ± 14.39 | 0.017 |
EF (mean, SD) | 67.29 (7.917) | 66.64 (7.708) | 0.3936 |
SF (mean, SD) | 38.18 (7.52) | 36.63 (6.799) | 0.1859 |
Table 2.
Frequency distribution of associated pathologies in BAV group (CoAo—coarctation of the aorta, BAV—bicuspid aortic valve, AS—aortic stenosis, AR—aortic regurgitation).
Table 2.
Frequency distribution of associated pathologies in BAV group (CoAo—coarctation of the aorta, BAV—bicuspid aortic valve, AS—aortic stenosis, AR—aortic regurgitation).
Pathology | BAV Group (n = 73) |
---|
Unoperated CoAo, n (%) | 2 (2.74) |
Operated CoAo, n (%) | 9 (12.33) |
Mild AS, n (%) | 22 (30.14) |
Moderated AS, n (%) | 8 (10.96) |
Severe AS, n (%) | 8 (10.96) |
Mild AR, n (%) | 50 (68.49) |
Moderated AR, n (%) | 11 (15.07) |
Severe AR, n (%) | 2 (2.74) |
Aortopathy, n (%) | 30 (41.10) |
Table 3.
Comparison between absolute size and Z-score of aortic annulus, sinus of Valsalva, sinotubular junction, and ascending aorta of BAV group and control group (BAV—bicuspid aortic valve).
Table 3.
Comparison between absolute size and Z-score of aortic annulus, sinus of Valsalva, sinotubular junction, and ascending aorta of BAV group and control group (BAV—bicuspid aortic valve).
Parameters | BAV Group (n = 73) | Group Control (n = 55) | p Value |
---|
Aortic valve annulus (mm, mean, SD) | 22.22 (4.35) | 23.45 (27.83) | 0.0010 ** |
Aortic valve annulus Z-score (mean, SD) | 1.67 (1.47) | 3.13 (19.30) | <0.0001 ** |
Sinus of Valsalva (mm, mean, SD) | 25.56 (5.62) | 26.83 (31.36) | 0.0023 ** |
Sinus of Valsalva Z-score (mean, SD) | 0.521 (1.729) | −0.648 (1.207) | 0.0001 * |
Sinotubular junction (mm, mean, SD) | 23.41 (6.714) | 20.08 (6.007) | 0.0065 ** |
Sinotubular junction Z-score (mean, SD) | 1.735 (1.531) | 0.605 (0.994) | <0.0001 ** |
Ascending aorta (mm, mean, SD) | 30.95 (26.41) | 18.50 (7.927) | <0.0001 ** |
Ascending aorta Z-score (mean, SD) | 1.881 (1.992) | −0.437 (1.097) | <0.0001 ** |
Table 4.
Results of global and segmental longitudinal strain in control group (abbreviations: BIS—basal inferoseptal, MIS—mid-inferoseptal, AIS—apical inferoseptal, AAL—apical anterolateral, MAL—mid-anterolateral, BAL—basal anterolateral, BI—basal inferior, MI—mid-inferior, AI—apical inferior, AA—apical anterior, MA—mid-anterior, BA—basal anterior, BIL—basal inferolateral, MIL—mid-inferolateral, AIL—apical inferolateral, AAS—apical anteroseptal, MAS—mid-anteroseptal, BAS—basal anteroseptal).
Table 4.
Results of global and segmental longitudinal strain in control group (abbreviations: BIS—basal inferoseptal, MIS—mid-inferoseptal, AIS—apical inferoseptal, AAL—apical anterolateral, MAL—mid-anterolateral, BAL—basal anterolateral, BI—basal inferior, MI—mid-inferior, AI—apical inferior, AA—apical anterior, MA—mid-anterior, BA—basal anterior, BIL—basal inferolateral, MIL—mid-inferolateral, AIL—apical inferolateral, AAS—apical anteroseptal, MAS—mid-anteroseptal, BAS—basal anteroseptal).
Parameters | Control Group (n = 55) |
---|
GLS A4C (mean, SD) | −21.25 (7.17) |
BIS (mean, SD) | −19.46 (6.82) |
MIS (mean, SD) | −22.92 (5.04) |
AIS (mean, SD) | −24.72 (7.20) |
AAL (mean, SD) | −21.53 (7.23) |
MAL (mean, SD) | −19.48 (6.70) |
BAL (mean, SD) | −27.80 (8.49) |
GLS A2C (mean, SD) | −21.52 (9.07) |
BI (mean, SD) | −22.13 (8.14) |
MI (mean, SD) | −25.77 (5.89) |
AI (mean, SD) | −24.94 (7.19) |
AA (mean, SD) | −18.60 (9.23) |
MA (mean, SD) | −21.15 (5.18) |
BA (mean, SD) | −29.15 (8.42) |
GLS A3C (mean, SD) | −22.73 (4.01) |
BIL (mean, SD) | −27.52 (12.44) |
MIL (mean, SD) | −22.40 (7.87) |
AIL (mean, SD) | −22.86 (10.92) |
AAS (mean, SD) | −22.62 (10.41) |
MAS (mean, SD) | −21.63 (7.53) |
BAS (mean, SD) | −19.79 (10.42) |
Table 5.
GLS correlations between BAV group and control group (abbreviations: BIS—basal inferoseptal, MIS—mid-inferoseptal, AIS—apical inferoseptal, AAL—apical anterolateral, MAL—mid-anterolateral, BAL—basal anterolateral, BI—basal inferior, MI—mid-inferior, AI—apical inferior, AA—apical anterior, MA—mid-anterior, BA—basal anterior, BIL—basal inferolateral, MIL—mid-inferolateral, AIL—apical inferolateral, AAS—apical anteroseptal, MAS—mid-anteroseptal, BAS—basal anteroseptal).
Table 5.
GLS correlations between BAV group and control group (abbreviations: BIS—basal inferoseptal, MIS—mid-inferoseptal, AIS—apical inferoseptal, AAL—apical anterolateral, MAL—mid-anterolateral, BAL—basal anterolateral, BI—basal inferior, MI—mid-inferior, AI—apical inferior, AA—apical anterior, MA—mid-anterior, BA—basal anterior, BIL—basal inferolateral, MIL—mid-inferolateral, AIL—apical inferolateral, AAS—apical anteroseptal, MAS—mid-anteroseptal, BAS—basal anteroseptal).
Parameter | BAV Group (n = 73) | Control Group (n = 55) | p |
---|
GLS A4C (mean, SD) | −20.49 (4.89) | −21.25 (7.17) | 0.0229 ** |
BIS (mean, SD) | −17.13 (8.21) | −19.46 (6.82) | 0.0430 ** |
MIS (mean, SD) | −21.69 (6.52) | −22.92 (5.04) | 0.3220 * |
AIS (mean, SD) | −25.24 (9.55) | −24.72 (7.20) | 0.7700 * |
AAL (mean, SD) | −21.49 (9.08) | −21.53 (7.23) | 0.9819 * |
MAL (mean, SD) | −16.03 (8.45) | −19.48 (6.70) | 0.0336 * |
BAL (mean, SD) | −25.56 (12.24) | −27.80 (8.49) | 0.4213 ** |
GLS A2C (mean, SD) | −21.65 (4.96) | −21.52 (9.07) | 0.2907 ** |
BI (mean, SD) | −18.79 (8.64) | −22.13 (8.14) | 0.0742 ** |
MI (mean, SD) | −24.92 (7.17) | −25.77 (5.89) | 0.5700 * |
AI (mean, SD) | −28.03 (8.05) | −24.94 (7.19) | 0.0678 * |
AA (mean, SD) | −20.23 (8.70) | −18.60 (9.23) | 0.4010 * |
MA (mean, SD) | −17.60 (9.09) | −21.15 (5.18) | 0.0407 ** |
BA (mean, SD) | −22.73 (12.69) | −29.15 (8.42) | 0.0231 ** |
GLS A3C (mean, SD) | −21.80 (5.24) | −22.73 (4.01) | 0.3078 ** |
BIL (mean, SD) | −26.64 (11.71) | −27.52 (12.44) | 0.7342 * |
MIL (mean, SD) | −20.46 (9.26) | −22.40 (7.87) | 0.3154 * |
AIL (mean, SD) | −24.09 (8.68) | −22.86 (10.92) | 0.5515 * |
AAS (mean, SD) | −24.28 (11.73) | −22.62 (10.41) | 0.5041 * |
MAS (mean, SD) | −19.79 (7.47) | −21.63 (7.53) | 0.3730 ** |
BAS (mean, SD) | −17.07 (8.97) | −19.79 (10.42) | 0.1891 * |
Table 6.
Correlation of GLS values according to patient gender in the BAV group (abbreviations: BIS—basal inferoseptal, MIS—mid-inferoseptal, AIS—apical inferoseptal, AAL—apical anterolateral, MAL—mid-anterolateral, BAL—basal anterolateral, BI—basal inferior, MI—mid-inferior, AI—apical inferior, AA—apical anterior, MA—mid-anterior, BA—basal anterior, BIL—basal inferolateral, MIL—mid-inferolateral, AIL—apical inferolateral, AAS—apical anteroseptal, MAS—mid-anteroseptal, BAS—basal anteroseptal).
Table 6.
Correlation of GLS values according to patient gender in the BAV group (abbreviations: BIS—basal inferoseptal, MIS—mid-inferoseptal, AIS—apical inferoseptal, AAL—apical anterolateral, MAL—mid-anterolateral, BAL—basal anterolateral, BI—basal inferior, MI—mid-inferior, AI—apical inferior, AA—apical anterior, MA—mid-anterior, BA—basal anterior, BIL—basal inferolateral, MIL—mid-inferolateral, AIL—apical inferolateral, AAS—apical anteroseptal, MAS—mid-anteroseptal, BAS—basal anteroseptal).
Parameter | Male (n = 55) | Female (n = 18) | p-Value |
---|
GLS A4C (mean, SD) | −20.10 ± 5.27 | −21.60 ± 3.66 | 0.193 |
BIS (mean, SD) | −14.65 (−19.73–−11.12) | −18.25 (−21.72–−16.02) | 0.016 |
MIS (mean, SD) | −21.14 ± 6.87 | −23.29 ± 5.42 | 0.185 |
AIS (mean, SD) | −26.28 ± 10.15 | −22.22 ± 7.30 | 0.075 |
AAL (mean, SD) | −22.71 ± 9.15 | −17.97 ± 8.41 | 0.052 |
MAL (mean, SD) | −15.19 ± 8.07 | −18.46 ± 9.48 | 0.202 |
BAL (mean, SD) | −24.15 ± 11.87 | −29.66 ± 13.06 | 0.126 |
GLS A2C (mean, SD) | −21.18 ± 4.90 | −23.01 ± 5.15 | 0.201 |
BI (mean, SD) | −16.55 (−22.25–−12.95) | −20.40 (−26.08–−18.52) | 0.061 |
MI (mean, SD) | −25.03 ± 7.35 | −24.62 ± 7.04 | 0.837 |
AI (mean, SD) | −28.28 ± 8.34 | −27.30 ± 7.60 | 0.648 |
AA (mean, SD) | −20.61 ± 9.15 | −19.16 ± 7.68 | 0.516 |
MA (mean, SD) | −17.90 (−22.07–−13.45) | −18.80 (−24.12–−17.35) | 0.183 |
BA (mean, SD) | −22.40 (−29.52–−16.65) | −31.55 (−33.80–−25.62) | 0.019 |
GLS A3C (mean, SD) | −21.91 ± 5.18 | −21.48 ± 5.67 | 0.78 |
BIL (mean, SD) | −26.87 ± 12.07 | −25.97 ± 11.25 | 0.777 |
MIL (mean, SD) | −17.75 (−25.68–−14.47) | −22.25 (−25.03–−17.65) | 0.323 |
AIL (mean, SD) | −24.32 ± 8.61 | −23.43 ± 9.35 | 0.725 |
AAS (mean, SD) | −24.55 ± 10.86 | −23.49 ± 14.54 | 0.78 |
MAS (mean, SD) | −19.40 (−24.10–−15.45) | −19.85 (−21.03–−17.48) | 0.995 |
BAS (mean, SD) | −16.66 ± 8.42 | −18.27 ± 10.82 | 0.571 |
Table 7.
Comparison of the GLS values between the control group and the BAV group according to the associated pathology (abbreviations: BIS—basal inferoseptal, MIS—mid-inferoseptal, AIS—apical inferoseptal, AAL—apical anterolateral, MAL—mid-anterolateral, BAL—basal anterolateral, BI—basal inferior, MI—mid-inferior, AI—apical inferior, AA—apical anterior, MA—mid-anterior, BA—basal anterior, BIL—basal inferolateral, MIL—mid-inferolateral, AIL—apical inferolateral, AAS—apical anteroseptal, MAS—mid-anteroseptal, BAS—basal anteroseptal).
Table 7.
Comparison of the GLS values between the control group and the BAV group according to the associated pathology (abbreviations: BIS—basal inferoseptal, MIS—mid-inferoseptal, AIS—apical inferoseptal, AAL—apical anterolateral, MAL—mid-anterolateral, BAL—basal anterolateral, BI—basal inferior, MI—mid-inferior, AI—apical inferior, AA—apical anterior, MA—mid-anterior, BA—basal anterior, BIL—basal inferolateral, MIL—mid-inferolateral, AIL—apical inferolateral, AAS—apical anteroseptal, MAS—mid-anteroseptal, BAS—basal anteroseptal).
Parameter | Group 1—Control Group (n = 54) | Group 2—AS (n = 38) | Group 3—CoA (n = 11) | Group 4—Aop (n = 30) | Group 5—AR (n = 61) | p-Value |
---|
GLS A4C (mean, SD) | −22.10 (−24.00–−19.95) | −19.85 (−21.75–−17.43) | −17.90 (−21.40–−16.25) | −20.90 (−22.35–−17.40) | −20.90 (−23.55–−17.85) | 0.1 |
BIS (mean, SD) | −18.85 (−23.58–−15.57) | −15.15 (−19.02–−11.12) | −15.00 (−17.95–−13.40) | −13.70 (−18.25–−9.90) | −16.20 (−20.20–−11.60) | 0.022 |
MIS (mean, SD) | −22.92 ± 5.10 | −21.84 ± 6.87 | −21.17 ± 7.96 | −21.37 ± 7.25 | −21.98 ± 6.35 | 0.874 |
AIS (mean, SD) | −24.72 ± 7.30 | −24.59 ± 8.42 | −27.76 ± 10.68 | −24.75 ± 10.63 | −25.74 ± 10.13 | 0.854 |
AAL (mean, SD) | −21.53 ± 7.33 | −21.67 ± 9.09 | −23.98 ± 9.19 | −22.89 ± 9.66 | −21.93 ± 9.45 | 0.917 |
MAL (mean, SD) | −19.48 ± 6.79 | −14.97 ± 8.55 | −10.32 ± 3.87 | −16.35 ± 9.88 | −16.64 ± 8.75 | 0.018 |
BAL (mean, SD) | −26.95 (−30.80–−21.73) | −26.15 (−34.08–−18.57) | −21.80 (−31.90–−6.50) | −26.80 (−33.15–−20.75) | −26.60 (−34.45–−18.20) | 0.792 |
GLS A2C (mean, SD) | −22.10 (−25.65–−19.70) | −20.75 (−24.32–−18.75) | −19.70 (−22.10–−18.90) | −21.80 (−25.20–−19.00) | −21.90 (−25.20–−19.00) | 0.368 |
BI (mean, SD) | −21.50 (−25.40–−16.35) | −18.40 (−21.55–−12.78) | −16.00 (−22.00–−11.85) | −18.30 (−22.25–−13.10) | −19.10 (−23.75–−13.60) | 0.217 |
MI (mean, SD) | −25.77 ± 5.99 | −24.25 ± 7.16 | −22.79 ± 7.27 | −25.50 ± 8.20 | −25.82 ± 6.92 | 0.622 |
AI (mean, SD) | −24.70 (−27.25–−22.15) | −27.05 (−31.10–−21.53) | −27.10 (−33.40–−23.20) | −27.80 (−33.20–−22.70) | −27.80 (−34.05–−23.05) | 0.213 |
AA (mean, SD) | −18.60 ± 9.38 | −18.96 ± 7.70 | −17.52 ± 4.89 | −21.03 ± 7.31 | −20.57 ± 8.68 | 0.559 |
MA (mean, SD) | −21.20 (−24.30–−16.95) | −17.55 (−20.35–−13.45) | −17.50 (−21.50–−14.85) | −17.50 (−20.90–−12.00) | −18.00 (−23.05–−15.75) | 0.039 |
BA (mean, SD) | −29.15 ± 8.56 | −24.34 ± 9.50 | −23.53 ± 7.70 | −24.71 ± 9.14 | −24.61 ± 9.33 | 0.152 |
GLS A3C (mean, SD) | −22.80 (−24.35–−20.40) | −20.15 (−23.88–−16.88) | −20.20 (−21.70–−17.05) | −22.00 (−24.75–−18.45) | −21.40 (−26.05–−18.70) | 0.286 |
BIL (mean, SD) | −27.52 ± 12.64 | −25.22 ± 11.87 | −25.39 ± 11.83 | −25.24 ± 12.93 | −26.76 ± 12.08 | 0.921 |
MIL (mean, SD) | −23.80 (−27.60–−17.90) | −18.15 (−25.00–−13.68) | −19.50 (−27.90–−17.10) | −16.60 (−25.15–−11.60) | −21.70 (−25.75–−15.15) | 0.288 |
AIL (mean, SD) | −22.86 ± 11.10 | −23.34 ± 9.21 | −17.95 ± 7.74 | −24.16 ± 8.63 | −24.19 ± 9.00 | 0.355 |
AAS (mean, SD) | −22.62 ± 10.58 | −23.59 ± 12.27 | −24.35 ± 13.61 | −28.31 ± 11.29 | −24.79 ± 11.77 | 0.427 |
MAS (mean, SD) | −21.00 (−24.60–−15.30) | −18.90 (−21.77–−15.50) | −20.50 (−21.30–−12.70) | −19.70 (−25.30–−17.15) | −19.70 (−24.60–−17.10) | 0.587 |
BAS (mean, SD) | −21.10 (−26.65–−13.45) | −15.15 (−19.93–−10.20) | −13.20 (−16.90–−9.65) | −13.70 (−19.15–−9.85) | −16.80 (−21.45–−10.80) | 0.198 |
Table 8.
Post hoc analysis between control and BAV groups according to the associated pathology (A4C—apical four-chamber view, A2C—apical two-chamber view, BIS—basal inferoseptal, MAL—mid-anterolateral, MA—mid-anterior).
Table 8.
Post hoc analysis between control and BAV groups according to the associated pathology (A4C—apical four-chamber view, A2C—apical two-chamber view, BIS—basal inferoseptal, MAL—mid-anterolateral, MA—mid-anterior).
Post Hoc Analysis | |
---|
BIS A4C—(Mann–Whitney U) | p-value |
Group 1—Control group vs. Group 2—AS | 0.014 |
Group 1—Control group vs. Group 3—CoA | 0.058 |
Group 1—Control group vs. Group 4—Aortopathy | 0.003 |
Group 1—Control group vs. Group 5—AR | 0.043 |
Group 2—AS vs. Group 3—CoA | 0.95 |
Group 2—AS vs. Group 4—Aortopathy | 0.445 |
Group 2—AS vs. Group 5—AR | 0.427 |
Group 3—CoAo vs. Group 4—Aortopathy | 0.499 |
Group 3—CoAo vs. Group 5—AR | 0.617 |
Group 4—Aortopathy vs. Group 5—AR | 0.117 |
MAL A2C (Mann–Whitney U) | |
Group 1—Control group vs. Group 2—AS | 0.007 |
Group 1—Control group vs. Group 3—CoA | 0.067 |
Group 1—Control group vs. Group 4—Aortopathy | 0.008 |
Group 1—Control group vs. Group 5—AR | 0.082 |
Group 2—AS vs. Group 3—CoA | 0.92 |
Group 2—AS vs. Group 4—Aortopathy | 0.77 |
Group 2—AS vs. Group 5—AR | 0.247 |
Group 3—CoAo vs. Group 4—Aortopathy | 0.949 |
Group 3—CoAo vs. Group 5—AR | 0.401 |
Group 4—Aortopathy vs. Group 5—AR | 0.191 |
MAL A4C (Tukey test HSD) | |
Group 1—Control group vs. Group 2—AS | 0.137 |
Group 1—Control group vs. Group 3—CoA | 0.013 |
Group 1—Control group vs. Group 4—Aortopathy | 0.563 |
Group 1—Control group vs. Group 5—AR | 0.468 |
Group 2—AS vs. Group 3—CoA | 0.013 |
Group 2—AS vs. Group 4—Aortopathy | 0.563 |
Group 2—AS vs. Group 5—AR | 0.468 |
Group 3—CoAo vs. Group 4—Aortopathy | 0.563 |
Group 3—CoAo vs. Group 5—AR | 0.468 |
Group 4—Aortopathy vs. Group 5—AR | 0.468 |
Table 9.
Comparison of the GLS values between the control group and the BAV group according to the phenotype (abbreviations: BIS—basal inferoseptal, MIS—mid-inferoseptal, AIS—apical inferoseptal, AAL—apical anterolateral, MAL—mid-anterolateral, BAL—basal anterolateral, BI—basal inferior, MI—mid-inferior, AI—apical inferior, AA—apical anterior, MA—mid-anterior, BA—basal anterior, BIL—basal inferolateral, MIL—mid-inferolateral, AIL—apical inferolateral, AAS—apical anteroseptal, MAS—mid-anteroseptal, BAS—basal anteroseptal).
Table 9.
Comparison of the GLS values between the control group and the BAV group according to the phenotype (abbreviations: BIS—basal inferoseptal, MIS—mid-inferoseptal, AIS—apical inferoseptal, AAL—apical anterolateral, MAL—mid-anterolateral, BAL—basal anterolateral, BI—basal inferior, MI—mid-inferior, AI—apical inferior, AA—apical anterior, MA—mid-anterior, BA—basal anterior, BIL—basal inferolateral, MIL—mid-inferolateral, AIL—apical inferolateral, AAS—apical anteroseptal, MAS—mid-anteroseptal, BAS—basal anteroseptal).
Parameter | 0 AP | 0 LL | IA | IB | IC | p-Value |
---|
GLS A4C (mean, SD) | −17.51 ± 5.95 | −19.46 ± 2.63 | −17.70 ± 6.25 | −21.48 ± 5.21 | −20.87 ± 3.10 | 0.245 |
BIS (mean, SD) | −13.70 (−20.45–−10.95) | −15.50 (−18.50–−11.12) | −16.55 (−21.70–−11.88) | −17.40 (−20.25–−11.97) | −18.20 (−24.80–−16.25) | 0.43 |
MIS (mean, SD) | −21.63 ± 8.47 | −22.82 ± 6.51 | −18.05 ± 7.32 | −21.43 ± 6.53 | −20.07 ± 2.27 | 0.483 |
AIS (mean, SD) | −22.27 ± 12.65 | −25.11 ± 5.13 | −19.98 ± 13.05 | −26.51 ± 10.33 | −23.17 ± 6.93 | 0.982 |
AAL (mean, SD) | −23.83 ± 10.38 | −19.23 ± 6.85 | −20.80 ± 7.82 | −22.07 ± 10.41 | −21.57 ± 5.42 | 0.869 |
MAL (mean, SD) | −11.50 (−17.00–−9.25) | −14.30 (−18.88–−9.02) | −13.30 (−16.20–−9.90) | −16.55 (−21.98–−9.38) | −18.00 (−19.85–−15.60) | 0.65 |
BAL (mean, SD) | −21.29 ± 12.53 | −24.74 ± 12.18 | −19.45 ± 15.80 | −26.91 ± 12.64 | −25.30 ± 6.38 | 0.679 |
GLS A2C (mean, SD) | −18.44 ± 4.42 | −21.09 ± 6.54 | −20.15 ± 3.81 | −22.88 ± 4.38 | −17.77 ± 0.97 | 0.077 |
BI (mean, SD) | −19.90 ± 15.21 | −16.94 ± 7.82 | −20.73 ± 4.30 | −19.25 ± 8.34 | −18.67 ± 4.03 | 0.804 |
MI (mean, SD) | −21.80 (−24.80–−20.40) | −26.15 (−30.65–−16.85) | −21.40 (−22.88–−19.38) | −25.05 (−28.95–−21.77) | −25.30 (−27.05–−21.65) | 0.699 |
AI (mean, SD) | −30.10 (−34.40–−24.45) | −24.95 (−29.23–−20.53) | −24.55 (−28.93–−21.78) | −29.85 (−35.20–−22.85) | −20.00 (−22.80–−17.35) | 0.209 |
AA (mean, SD) | −26.00 ± 12.49 | −17.72 ± 5.75 | −17.15 ± 7.19 | −21.60 ± 8.32 | −6.97 ± 7.22 | 0.081 |
MA (mean, SD) | −16.20 (−20.95–−11.55) | −17.30 (−22.73–−12.72) | −19.25 (−22.77–−15.55) | −18.00 (−23.73–−16.85) | −17.80 (−18.70–−11.20) | 0.861 |
BA (mean, SD) | −19.90 (−27.10–−15.70) | −28.25 (−31.85–−14.97) | −21.05 (−26.57–−15.12) | −24.35 (−31.70–−18.85) | −17.50 (−27.30–−17.10) | 0.923 |
GLS A3C (mean, SD) | −22.17 ± 2.88 | −22.20 ± 6.28 | −18.30 ± 1.56 | −21.77 ± 5.26 | −21.27 ± 8.22 | 0.566 |
BIL (mean, SD) | −35.39 ± 14.87 | −30.04 ± 11.91 | −24.07 ± 4.36 | −23.62 ± 10.89 | −22.17 ± 7.93 | 0.155 |
MIL (mean, SD) | −19.20 (−22.55–−12.35) | −23.90 (−28.68–−16.98) | −12.65 (−15.82–−9.18) | −18.20 (−25.67–−15.30) | −22.60 (−26.30–−22.15) | 0.044 |
AIL (mean, SD) | −22.37 ± 8.11 | −25.08 ± 9.02 | −22.75 ± 4.06 | −23.72 ± 9.15 | −26.40 ± 13.08 | 0.907 |
AAS (mean, SD) | −23.57 ± 10.99 | −24.25 ± 15.40 | −22.12 ± 7.22 | −23.93 ± 10.16 | −27.03 ± 21.77 | 0.941 |
MAS (mean, SD) | −15.39 ± 8.39 | −19.33 ± 7.83 | −15.43 ± 4.29 | −21.12 ± 6.95 | −14.17 ± 4.37 | 0.043 |
BAS (mean, SD) | −9.13 ± 6.74 | −15.43 ± 9.45 | −13.70 ± 4.50 | −19.34 ± 9.28 | −18.77 ± 4.35 | 0.08 |
Table 10.
Post hoc analysis of the BAV group according to phenotype (abbreviations: A3C—apical three-chamber view, MIL—mid-inferolateral, MAS—mid-anteroseptal).
Table 10.
Post hoc analysis of the BAV group according to phenotype (abbreviations: A3C—apical three-chamber view, MIL—mid-inferolateral, MAS—mid-anteroseptal).
GLS A3C MIL | p-Value | GLS A3C MAS | p-Value |
---|
0 AP vs. 0 LL | 0.154 | 0 AP vs. 0 LL | 0.181 |
0 AP vs. IA | 0.315 | 0 AP vs. IA | 0.776 |
0 AP vs. IB | 0.481 | 0 AP vs. IB | 0.103 |
0 AP vs. IC | 0.183 | 0 AP vs. IC | 0.833 |
0 LL vs. IA | 0.029 | 0 LL vs. IA | 0.143 |
0 LL vs. IB | 0.229 | 0 LL vs. IB | 0.589 |
0 LL vs. IC | 0.875 | 0 LL vs. IC | 0.146 |
IA vs. IB | 0.051 | IA vs. IB | 0.099 |
IA vs. IC | 0.057 | IA vs. IC | 0.858 |
IB vs. IC | 0.317 | IB vs. IC | 0.068 |